Project Details
Description
Transfer in of Clinical Trial from Usyd
| Acronym | TEMPO-2 |
|---|---|
| Status | Active |
| Effective start/end date | 7/08/24 → 3/04/29 |
A phase 3, double-blind, randomized, placebo-controlled, parallel-group, flexible-dose, 27 week trial to evaluate the efficacy, safety, and tolerability of Tavapadon in early Parkinson's Disease (TEMPO-2 trial)
- Lewis, Simon (Primary Chief Investigator)
- West, Stacey (Other)
- Harvey, Caroline (Other)
Project: Research